Leukaemia (all types)
Prepared with OnCo (onco.cc/prep/leukaemia/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
12 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Flow cytometry immunophenotype, Cytogenetics and fusion genes, Mutations, Measurable residual disease by flow or PCR), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (diagnosis), which of the standard options do you recommend and why?
- 6.For my situation (treatment), which of the standard options do you recommend and why?
- 7.For my situation (supportive care), which of the standard options do you recommend and why?
- 8.Are there clinical trials I could join, for example of Menin inhibitors, CAR-T cell therapy?
- 9.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 10.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 11.I read that “Adult ALL and TP53-mutated AML still have poor outcomes”. How does that affect my plan?
- 12.I read that “Infant and relapsed childhood leukaemias”. How does that affect my plan?
Tests and results to bring
Diagnosis: Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.
Biomarker results to ask for: Flow cytometry immunophenotype, Cytogenetics and fusion genes (BCR-ABL1, PML-RARA, KMT2A), Mutations (FLT3, NPM1, IDH1/2, TP53, IGHV status), Measurable residual disease by flow or PCR.
Scans and tests linked to this cancer: Cytogenetics and FISH, Flow cytometers, Multiparameter flow cytometry MRD, TPMT and NUDT15 genotyping before thiopurines, Ex vivo drug sensitivity screening in blood cancers (EXALT).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Treatment: By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL. (Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML))
- Supportive care: Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment. (Growth factors: G-CSF and febrile neutropenia prevention, Transfusion support and anaemia management)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.